Abstract: MCP-1 binding molecules are provided comprising at least one immunoglobulin heavy chain variable domain (VH) comprising hypervariable regions CDR1, CDR2 and CDR3 of sequence as defined, for use in the treatment of MCP-1 or eotaxin-mediated diseases or disorders.

Abstract: A cyclosporin of the formula ##STR1## wherein A is a residue of the formula ##STR2## wherein R is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy or C.sub.1-3 alkylthio; halo-substituted-C.sub.1-3 alkyl, -C.sub.1-3 alkoxy or -C.sub.1-3 alkylthio; hydroxy-substituted-C.sub.1-3 alkyl, -C.sub.2-3 alkoxy or -C.sub.2-3 alkylthio; or amino or mono- or di-(C.sub.1-2 alkyl)-amino,X is oxygen or sulphur,--x--y-- is --CH.dbd.CH-- (trans) or --CH.sub.2 --CH.sub.2 --,B is -.alpha.Abu-, -Val-, -Thr- or -Nva- andQ is -(D)Ala-; -(D)Ser-; -[O-(2-hydroxyethyl)(D)Ser]-; or -[O-acyl(D)Ser]- or -[O-(2-acyloxy ethyl)(D)Ser]-in which the acyl residue is physiologically hydrolysable and acceptable, are useful in the topical treatment of asthma.

Abstract: This invention provides new compounds of formula I, ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 or 2 carbon atoms;R.sub.2 is hydrogen or halogen of atomic number from 9 to 35;A.I. each of R.sub.3 and R.sub.4 is hydrogen, orIi. R.sub.3 and R.sub.4 together are oxygen, andI. R.sub.5 is hydrogen or alkyl of 1 to 4 carbon atoms, orIi. R.sub.5 and R.sub.7 are attached to the same carbon atom, and form an alkylene chain of 3 to 6 carbon atoms, orB. when A as defined hereinafter is --(CH.sub.2).sub.2 --R.sub.3 is hydrogen and R.sub.4 and R.sub.5 together form a bond;R.sub.6 is hydrogen or alkyl of 1 to 4 carbon atoms; andA is --(CH.sub.2).sub.n --,Wherein n is 0, 1 or 2 depending on the following:n may be 0 provided that R.sub.3 and R.sub.4 together are oxygen;n may be 1 provided that (i) at least one of R.sub.5, R.sub.6 and R.sub.7 is alkyl of 1 to 4 carbon atoms; (ii) R.sub.5 and R.sub.7 together form an alkylene chain of 3 to 6 carbon atoms; or (iii) R.sub.2 is halogen, R.sub.3 and R.sub.